Literature DB >> 17977830

An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/Cip1 in response to 5-aza-2'-deoxycytidine treatment.

Haiying Wang1, Ying Zhao, Lian Li, Michael A McNutt, Lipeng Wu, Shaoli Lu, Yu Yu, Wen Zhou, Jingnan Feng, Guolin Chai, Yang Yang, Wei-Guo Zhu.   

Abstract

Most agents that damage DNA act through posttranslational modifications of p53 and activate its downstream targets. However, whether cellular responses to nucleoside analogue-induced DNA damage also operate through p53 posttranslational modification has not been reported. In this study, the relationship between p53 activation and its posttranslational modifications was investigated in the human cancer cell lines A549 and HCT116 in response to 5-aza-2'-deoxycytidine (5-aza-CdR) or cytarabine treatment. 5-Aza-CdR induces p53 posttranslational modifications through activation of an ATM- and Rad3-related (ATR) signaling pathway, and 5-aza-CdR-induced association of replication protein A with chromatin is required for the binding of ATR to chromatin. Upon treatment with 5-aza-CdR, ATR activation is clearly associated with p53 phosphorylation at Ser(15), but not at Thr(18), Ser(20), or Ser(37). This specific p53 phosphorylation at Ser(15) in turn results in acetylation of p53 at Lys(320) and Lys(373)/Lys(382) through transcriptional cofactors p300/CBP-associated factor and p300, respectively. These p53 posttranslational modifications are directly responsible for 5-aza-CdR induced p21(Waf1/Cip1) expression because the binding activity of acetylated p53 at Lys(320)/Lys(373)/Lys(382) to the p21(Waf1/Cip1) promoter, as well as p21(Waf1/Cip1) expression itself are significantly increased after 5-aza-CdR treatment. It is of interest that p53 phosphorylation at Ser(15) and acetylations at Lys(320)/Lys(373)/Lys(382) mutually interact in the 5-aza-CdR induced p21(Waf1/Cip1) expression shown by transfection of artificially mutated p53 expression vectors including S15A, K320R, and K373R/K382R into p53-null H1299 cells. These data taken together show for the first time that 5-aza-CdR activates the ATR signaling pathway, which elicits a specific p53 phosphorylation-acetylation cascade to induce p21(Waf1/Cip1) expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17977830     DOI: 10.1074/jbc.M702454200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  The multifunctional sorting protein PACS-2 regulates SIRT1-mediated deacetylation of p53 to modulate p21-dependent cell-cycle arrest.

Authors:  Katelyn M Atkins; Laura L Thomas; Jonathan Barroso-González; Laurel Thomas; Sylvain Auclair; Jun Yin; Hyeog Kang; Jay H Chung; Jimmy D Dikeakos; Gary Thomas
Journal:  Cell Rep       Date:  2014-08-21       Impact factor: 9.423

Review 2.  Dying to protect: cell death and the control of T-cell homeostasis.

Authors:  Kun-Po Li; Sharmila Shanmuganad; Kaitlin Carroll; Jonathan D Katz; Michael B Jordan; David A Hildeman
Journal:  Immunol Rev       Date:  2017-05       Impact factor: 12.988

3.  Temporal and differential regulation of KAISO-controlled transcription by phosphorylated and acetylated p53 highlights a crucial regulatory role of apoptosis.

Authors:  Seo-Hyun Choi; Dong-In Koh; Su-Yeon Cho; Min-Kyeong Kim; Kyung-Sup Kim; Man-Wook Hur
Journal:  J Biol Chem       Date:  2019-07-11       Impact factor: 5.157

4.  Identification of signaling pathways mediating cell cycle arrest and apoptosis induced by Porphyromonas gingivalis in human trophoblasts.

Authors:  Hiroaki Inaba; Masae Kuboniwa; Hideyuki Sugita; Richard J Lamont; Atsuo Amano
Journal:  Infect Immun       Date:  2012-06-11       Impact factor: 3.441

5.  Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.

Authors:  Barbora Brodská; Petra Otevřelová; Aleš Holoubek
Journal:  Mol Cell Biochem       Date:  2010-12-14       Impact factor: 3.396

Review 6.  Therapy with azanucleosides for myelodysplastic syndromes.

Authors:  Alfonso Quintás-Cardama; Fabio P S Santos; Guillermo Garcia-Manero
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

Review 7.  Cancer epigenetics: linking basic biology to clinical medicine.

Authors:  Hsing-Chen Tsai; Stephen B Baylin
Journal:  Cell Res       Date:  2011-02-15       Impact factor: 25.617

8.  DNA demethylating antineoplastic strategies: a comparative point of view.

Authors:  Stefano Amatori; Irene Bagaloni; Benedetta Donati; Mirco Fanelli
Journal:  Genes Cancer       Date:  2010-03

9.  The autophagy-senescence connection in chemotherapy: must tumor cells (self) eat before they sleep?

Authors:  Rachel W Goehe; Xu Di; Khushboo Sharma; Molly L Bristol; Scott C Henderson; Kristoffer Valerie; Francis Rodier; Albert R Davalos; David A Gewirtz
Journal:  J Pharmacol Exp Ther       Date:  2012-08-27       Impact factor: 4.030

10.  p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.

Authors:  Petra A Link; Maria R Baer; Smitha R James; David A Jones; Adam R Karpf
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.